What Analysts Recommend for Medtronic ahead of Fiscal 1Q18 Results
Medtronic (MDT) will announce its fiscal 1Q18 results on August 2, 2017.
For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.
In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion.
In fiscal 4Q17, Medtronic’s revenue came in at $7.9 billion, representing YoY (year-over-year) growth of ~5%.
In addition to selling dialysis products, Fresenius Medical Care also offers dialysis treatment and associated laboratory services to patients through its network of 3,690 clinics.
In 2Q17, Fresenius Medical Care (FMS) reported revenues close to 3.3 billion euros, which represents year-over-year growth of ~11%.
In 1H17, Fresenius Medical Care (FMS) earned ~1.6 billion euros from the sale of dialysis products, which equals year-over-year growth of 8% on a reported basis.
For fiscal 2017, Wall Street analysts have projected Fresenius Medical Care’s net profit margins to be close to 6.2%, which is a YoY decline of ~70 basis points.
For fiscal 2017, Wall Street analysts have projected Fresenius Medical Care’s revenues to be close to $20.8 billion, which equals YoY growth of ~16.0%.
In 1H17, Fresenius Medical Care (FMS) reported revenues close to 9.0 billion euros, which represents 14% YoY growth. At the end of 2Q17, the company operated 3,690 dialysis clinics around the world.
Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.
Dentsply Sirona (XRAY) closed at $55.30 on August 11, 2017. The company was trading at its 52-week low of $54.50 on the day.
In 2Q17, Dentsply Sirona’s (XRAY) Dental and Healthcare Consumables business contributed ~56% to the company’s total revenues and registered sales of ~$554 million.
In 2Q17, Dentsply Sirona’s (XRAY) Technologies business contributed ~44% to the company’s total revenues and registered sales of ~$439 million.
Dentsply Sirona made a downward revision to its fiscal 2017 guidance during the company’s 2Q17 earnings results announcement on August 9, 2017.
Dentsply Sirona (XRAY) reported its 2Q17 earnings on August 9. The company earned revenues of ~$992.7 million, registering a year-over-year decline of ~2.9%.
Varian Medical Systems (VAR) closed at $96.20 on August 9, 2017. It has a 50-day moving average of $102.30, and a 200-day moving average of $93.20. On August 9, 2017, Varian…
Year-over-year, Varian Medical Systems (VAR) expects its 4Q17 revenue to be flat or fall. According to the company, headwinds from the euro, British pound, and Japanese yen are expected to have…
The proton therapy market is a highly lucrative opportunity area for Varian Medical Systems (VAR). Proton therapy uses protons for treating cancer instead of X-rays. According to a Medgadget report,…
The Halcyon system, Varian Medical Systems’ (VAR) recently launched cancer treatment device, aims to simplify and enhance IMRT (image-guided volumetric intensity modulated radiotherapy). The device has received clearance by the FDA…